Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GPCR |
---|---|---|
09:32 ET | 3382 | 38.39 |
09:34 ET | 715 | 37.56 |
09:36 ET | 500 | 37.532 |
09:39 ET | 400 | 37.69 |
09:43 ET | 671 | 37.745 |
09:45 ET | 911 | 37.98 |
09:48 ET | 900 | 38.3 |
09:50 ET | 300 | 37.84 |
09:52 ET | 600 | 37.78 |
09:54 ET | 900 | 37.66 |
09:56 ET | 1050 | 37.63 |
09:57 ET | 250 | 37.4028 |
09:59 ET | 600 | 37.59 |
10:01 ET | 500 | 37.65 |
10:03 ET | 796 | 37.67 |
10:06 ET | 2100 | 37.33 |
10:08 ET | 300 | 37.3149 |
10:10 ET | 3994 | 37.16 |
10:12 ET | 8115 | 37.37 |
10:14 ET | 559 | 37.27 |
10:15 ET | 2922 | 37.295 |
10:17 ET | 100 | 37.24 |
10:19 ET | 1100 | 37.305 |
10:21 ET | 1583 | 37.325 |
10:26 ET | 690 | 37.3 |
10:28 ET | 4300 | 37.5 |
10:30 ET | 3043 | 37.63 |
10:32 ET | 403 | 37.5 |
10:33 ET | 6310 | 37.575 |
10:35 ET | 3600 | 37.56 |
10:37 ET | 1950 | 37.56 |
10:39 ET | 1121 | 37.48 |
10:42 ET | 100 | 37.525 |
10:44 ET | 1179 | 37.56 |
10:46 ET | 1219 | 37.47 |
10:48 ET | 100 | 37.42 |
10:50 ET | 4101 | 37.43 |
10:51 ET | 600 | 37.32 |
10:53 ET | 2293 | 37.31 |
10:55 ET | 900 | 37.235 |
10:57 ET | 2400 | 37.2 |
11:00 ET | 3558 | 37.265 |
11:02 ET | 1550 | 37.305 |
11:04 ET | 12034 | 37.315 |
11:06 ET | 8615 | 37.275 |
11:08 ET | 2700 | 37.35 |
11:09 ET | 400 | 37.315 |
11:11 ET | 3168 | 37.16 |
11:13 ET | 4689 | 37.2495 |
11:15 ET | 2574 | 37.34 |
11:18 ET | 1366 | 37.39 |
11:20 ET | 697 | 37.31 |
11:22 ET | 4438 | 37.56 |
11:26 ET | 200 | 37.48 |
11:27 ET | 1949 | 37.57 |
11:29 ET | 500 | 37.62 |
11:31 ET | 500 | 37.6 |
11:33 ET | 753 | 37.66 |
11:36 ET | 1733 | 37.7 |
11:38 ET | 500 | 37.77 |
11:40 ET | 800 | 37.74 |
11:42 ET | 2749 | 37.86 |
11:44 ET | 300 | 37.855 |
11:45 ET | 200 | 37.93 |
11:47 ET | 673 | 37.93 |
11:49 ET | 22752 | 37.98 |
11:51 ET | 450 | 37.935 |
11:54 ET | 1525 | 37.75 |
11:56 ET | 1000 | 37.615 |
11:58 ET | 100 | 37.53 |
12:00 ET | 632 | 37.5838 |
12:02 ET | 100 | 37.52 |
12:03 ET | 3866 | 37.68 |
12:05 ET | 500 | 37.7 |
12:07 ET | 100 | 37.595 |
12:09 ET | 500 | 37.575 |
12:12 ET | 1075 | 37.51 |
12:14 ET | 1000 | 37.46 |
12:16 ET | 100 | 37.465 |
12:18 ET | 100 | 37.4575 |
12:20 ET | 1500 | 37.4 |
12:21 ET | 200 | 37.4083 |
12:23 ET | 2254 | 37.4 |
12:25 ET | 2422 | 37.445 |
12:27 ET | 400 | 37.385 |
12:30 ET | 100 | 37.375 |
12:32 ET | 733 | 37.375 |
12:34 ET | 11333 | 37.63 |
12:36 ET | 300 | 37.585 |
12:38 ET | 700 | 37.58 |
12:39 ET | 300 | 37.64 |
12:41 ET | 900 | 37.53 |
12:43 ET | 300 | 37.575 |
12:45 ET | 2356 | 37.5 |
12:48 ET | 918 | 37.47 |
12:50 ET | 750 | 37.51 |
12:52 ET | 350 | 37.48 |
12:56 ET | 999 | 37.515 |
12:57 ET | 1804 | 37.545 |
12:59 ET | 1900 | 37.49 |
01:01 ET | 500 | 37.495 |
01:03 ET | 608 | 37.475 |
01:06 ET | 100 | 37.48 |
01:08 ET | 3104 | 37.585 |
01:10 ET | 100 | 37.585 |
01:12 ET | 600 | 37.51 |
01:14 ET | 1101 | 37.52 |
01:17 ET | 585 | 37.49 |
01:19 ET | 1895 | 37.73 |
01:21 ET | 800 | 37.7 |
01:24 ET | 630 | 37.74 |
01:30 ET | 595 | 37.71 |
01:32 ET | 756 | 37.715 |
01:33 ET | 337 | 37.72 |
01:35 ET | 900 | 37.625 |
01:37 ET | 300 | 37.67 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Structure Therapeutics Inc | 2.1B | -16.2x | --- |
Apogee Therapeutics Inc | 2.2B | -18.2x | --- |
Iovance Biotherapeutics Inc | 2.1B | -4.0x | --- |
CG Oncology Inc | 2.1B | -27.8x | --- |
Janux Therapeutics Inc | 2.0B | -31.8x | --- |
Vera Therapeutics Inc | 1.9B | -17.3x | --- |
Structure Therapeutics Inc. is a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases. It is focused on G-protein coupled receptors (GPCRs) as a therapeutic target class. Its product candidates include GSBR-1290, Amylin, glucose-dependent insulinotropic polypeptide receptor (GIPR), GCGR, ANPA-0073 and LTSE-2578. It is developing GSBR-1290, its oral small molecule product candidate targeting the validated glucagon-like-peptide-1 receptor (GLP-1R) for the treatment of type 2 diabetes mellitus (T2DM) and obesity. It is developing GLP-1R candidates, including dual GLP-1R/GIPR agonists and amylin agonists, each designed with customized properties to achieve additional benefit. It is developing ANPA-0073, an investigational oral small molecule APJR agonist, for the treatment of idiopathic pulmonary fibrosis (IPF). It is evaluating its LPA1R program, LTSE-2578 for IPF and progressive pulmonary fibrosis.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.1B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 57.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.32 |
Book Value | $9.76 |
P/E Ratio | -16.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.